诚达药业
(301201)
| 流通市值：38.38亿 | | | 总市值：54.71亿 |
| 流通股本：1.09亿 | | | 总股本：1.55亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 255,491,382.8 | 128,239,954.61 | 406,371,974.56 | 285,094,723.46 |
| 营业总成本 | 255,972,818.53 | 123,429,214.85 | 401,421,371.25 | 277,205,588.06 |
| 其他经营收益 | | | | |
| 营业利润 | 3,261,123.27 | 9,811,471.67 | -7,830,755.62 | 19,049,784.2 |
| 利润总额 | 2,135,918.21 | 9,360,876.29 | -13,263,854.17 | 17,974,191.67 |
| 净利润 | 2,292,610.28 | 7,021,784.79 | -11,961,222.21 | 16,793,052.05 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | -6,298,500 | - |
| 综合收益总额 | 2,292,610.28 | 7,021,784.79 | -18,259,722.21 | 16,793,052.05 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,320,125,469.41 | 1,301,015,531.2 | 1,304,301,465.96 | 1,295,581,161.23 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,030,536,504.98 | 1,031,183,508.32 | 1,045,581,633.76 | 1,072,993,509.41 |
| 资产总计 | 2,350,661,974.39 | 2,332,199,039.52 | 2,349,883,099.72 | 2,368,574,670.64 |
| 流动负债: | | | | |
| 流动负债合计 | 202,241,532.97 | 171,771,993.43 | 202,967,224.32 | 175,485,459.56 |
| 非流动负债: | | | | |
| 非流动负债合计 | 49,076,973.41 | 56,354,403.57 | 49,865,017.67 | 60,896,399.93 |
| 负债合计 | 251,318,506.38 | 228,126,397 | 252,832,241.99 | 236,381,859.49 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 2,096,743,312.24 | 2,101,445,558.77 | 2,094,443,605.42 | 2,129,530,406.8 |
| 股东权益合计 | 2,099,343,468.01 | 2,104,072,642.52 | 2,097,050,857.73 | 2,132,192,811.15 |
| 负债和股东权益合计 | 2,350,661,974.39 | 2,332,199,039.52 | 2,349,883,099.72 | 2,368,574,670.64 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 286,726,701.93 | 116,491,495.97 | 530,505,285.97 | 360,139,351.06 |
| 经营活动现金流出小计 | 243,493,123.19 | 127,904,004.11 | 496,487,538.55 | 293,677,453.14 |
| 经营活动产生的现金流量净额 | 43,233,578.74 | -11,412,508.14 | 34,017,747.42 | 66,461,897.92 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,888,248,982.6 | 885,934,787.19 | 8,264,418,640.22 | 5,847,578,456.83 |
| 投资活动现金流出小计 | 2,116,119,841.78 | 868,048,516.77 | 7,998,019,323.07 | 5,234,558,933.01 |
| 投资活动产生的现金流量净额 | -227,870,859.18 | 17,886,270.42 | 266,399,317.15 | 613,019,523.82 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 0 | - | 8,951,765.59 | 8,079,300 |
| 筹资活动现金流出小计 | 8,173,276.3 | 404,075.37 | 62,821,485.28 | 60,921,641.61 |
| 筹资活动产生的现金流量净额 | -8,173,276.3 | -404,075.37 | -53,869,719.69 | -52,842,341.61 |
| 汇率变动对现金及现金等价物的影响 | -1,650,501.55 | -773,506.1 | 776,311.8 | 641,316.71 |
| 现金及现金等价物净增加额 | -194,461,058.29 | 5,296,180.81 | 247,323,656.68 | 627,280,396.84 |
| 期末现金及现金等价物余额 | 229,803,769.29 | 429,561,008.39 | 424,264,827.58 | 804,221,567.74 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -194,461,058.29 | - | 247,323,656.68 | - |
最新报告期：2026-08-26| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 财通证券 | 华挺 | 0.50 | 1.06 | 1.96 | 2026-08-26 |